Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

By / / Business / 1 minute of reading


Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.

Jaime Grajales Benjumea—Getty Images



Source link

About The Author

Avatar of Lynne Doty
Lynne Doty is a news writer for politics, health, business, parenting, and finance. Lynne is an avid runner and enjoys spending time with her kids—who are both competitive swimmers—and her husband.

Start typing and press enter to search

Scroll to Top